EPIDEMIOLOGY AND HEALTH DATA INSIGHTS
Review Article
Apr 14, 2026 81 33

Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis

Manchuk Karzhaubayeva 1 * ,
Saltanat Kamenova 2,
Aida Kondybayeva 2,
Dana Ospanbekova 2,
Yerbol Oshakbayev 3
1 Department of General Medical Practice, Faculty of Medicine, Al-Farabi Kazakh National University, Almaty, Kazakhstan2 Asfendiyarov Kazakh National Medical University, Scientific and Educational Center «Neurology and Applied Neuroscience», Almaty, Kazakhstan3 Department of General Medical Practice, Kazakh-Russian Medical University, Almaty, Kazakhstan* Corresponding Author
Epidemiology and Health Data Insights, 2(3), 2026, ehdi037, https://doi.org/10.63946/ehdi/18359
Publication date: Apr 14, 2026
Full Text (PDF)

ABSTRACT

Multiple system atrophy (MSA) remains one of the most challenging neurodegenerative disorders to diagnose, clinically characterized by various combinations of levodopa-resistant parkinsonism, cerebellar, autonomic, and pyramidal dysfunction. Early diagnosis of this disease is challenging, with post-mortem studies showing that the accuracy of diagnosis is only 62-79%. Late diagnosis is common, with an average of 3-4 years from the onset of the first symptoms to diagnosis. Given that the average survival is about 7-9 years, early diagnosis is crucial for the patient's quality of life and effective treatment.
This article provides a comprehensive analysis of three distinct clinical cases (MSA-P, MSA-C, and Mixed phenotype), highlighting the critical role of the 2022 Movement Disorder Society (MDS) diagnostic criteria in refining clinical accuracy, offers a practical framework for clinicians to improve early detection and symptomatic management of MSA, ultimately aiming to enhance patient quality of life in the absence of a curative therapy.

KEYWORDS

Multiple System Atrophy Autonomic Failure Orthostatic Hypotension UMSARS 2022 MDS Criteria Α-Synuclein Neurodegeneration

CITATION (Vancouver)

Karzhaubayeva M, Kamenova S, Kondybayeva A, Ospanbekova D, Oshakbayev Y. Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis. Epidemiology and Health Data Insights. 2026;2(3):ehdi037. https://doi.org/10.63946/ehdi/18359
APA
Karzhaubayeva, M., Kamenova, S., Kondybayeva, A., Ospanbekova, D., & Oshakbayev, Y. (2026). Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis. Epidemiology and Health Data Insights, 2(3), ehdi037. https://doi.org/10.63946/ehdi/18359
Harvard
Karzhaubayeva, M., Kamenova, S., Kondybayeva, A., Ospanbekova, D., and Oshakbayev, Y. (2026). Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis. Epidemiology and Health Data Insights, 2(3), ehdi037. https://doi.org/10.63946/ehdi/18359
AMA
Karzhaubayeva M, Kamenova S, Kondybayeva A, Ospanbekova D, Oshakbayev Y. Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis. Epidemiology and Health Data Insights. 2026;2(3), ehdi037. https://doi.org/10.63946/ehdi/18359
Chicago
Karzhaubayeva, Manchuk, Saltanat Kamenova, Aida Kondybayeva, Dana Ospanbekova, and Yerbol Oshakbayev. "Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis". Epidemiology and Health Data Insights 2026 2 no. 3 (2026): ehdi037. https://doi.org/10.63946/ehdi/18359
MLA
Karzhaubayeva, Manchuk et al. "Clinical-Phenotypic Spectrum and Course Characteristics of Multiple System Atrophy: a Retrospective Case Series Analysis". Epidemiology and Health Data Insights, vol. 2, no. 3, 2026, ehdi037. https://doi.org/10.63946/ehdi/18359

REFERENCES

  1. Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology. 2015;85(5):404–12. https://doi.org/10.1212/wnl.0000000000001807
  2. Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al. Disease progression and prognostic factors in multiple system atrophy: a prospective cohort study. Neurobiol Dis. 2020;139:104813. https://doi.org/10.1016/j.nbd.2020.104813
  3. Poewe W, Stankovic I, Halliday G, et al. Multiple system atrophy. Nat Rev Dis Primers. 2022;8:56. https://doi.org/10.1038/s41572-022-00382-6
  4. Andreyev MN, Fedotova YU. Multiple system atrophy: diagnostic methods and biomarkers. Annals of Clinical and Experimental Neurology. 2022;16(4):54–61. (in Russ). https://doi.org/10.54101/acen.2022.4.7
  5. Quinn NP. How to diagnose Multiple System Atrophy. Mov Disord. 2005;20(12):5–10. https://doi.org/10.1002/mds.20534
  6. Dickson DW, Lin W, Liu WK, et al. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999;9(4):721–32. https://doi.org/10.1111/j.1750-3639.1999.tb00553.x
  7. Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133–4. https://doi.org/10.1002/mds.870120203
  8. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969;32:28–34. https://doi.org/10.1136/jnnp.32.1.28
  9. Gilman S. Parkinsonian syndromes. Clin Geriatr Med. 2006;22(4):827–42. https://doi.org/10.1016/j.cger.2006.06.007
  10. Kicherova OA, Reykhter LI. Modern ideas about multiple system atrophy (literature review). Meditsinskoe obrazovanie Urala. 2018;3:154–57. (in Russ). [No DOI provided]
  11. Florian K, Jose-Alberto P, Giovanna C-B. The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations. Mov Disord. 2022;37(12):2336-2341. https://doi.org/10.1002/mds.29215
  12. Zhang L, Cao B, Hou Y, et al. Fatigue in patients with multiple system atrophy: a prospective cohort study. Neurology. 2022;98(1):e73–82. https://doi.org/10.1212/wnl.0000000000012968
  13. Min L, Zhiyao W, Huifang S. Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials. J Neurol. 2024;271:2324–2344. https://doi.org/10.1007/s00415-024-12269-5
  14. Porto KJ, et al. COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. J Neurol Sci. 2021;429:117623. https://doi.org/10.1016/j.jns.2021.117623
  15. Sailer A, et al. A genome-wide association study in multiple system atrophy. Neurology. 2016;87(15):1591–1598. https://doi.org/10.1212/wnl.0000000000003782
  16. Zhao F, et al. Mutations of glucocerebrosidase gene and susceptibility to Parkinson’s disease: an updated meta-analysis in a European population. Neuroscience. 2016;320:239–246. https://doi.org/10.1016/j.neuroscience.2016.02.007
  17. Gu X, et al. Analysis of GWAS-linked variants in multiple system atrophy. Neurobiol Aging. 2018;67:201.e1-201.e4. https://doi.org/10.1016/j.neurobiolaging.2018.03.018
  18. Kalra DK, Raina A, Sohal S. Neurogenic orthostatic hypotension: state of the art and therapeutic strategies. Clin Med Insights Cardiol. 2020;14. https://doi.org/10.1177/1179546820953415
  19. Yamamoto T, Pellecchia MT, Sakakibara R. Autonomic dysfunction in multiple system atrophy. Front Neurol. 2022. https://doi.org/10.3389/fneur.2022.1048895
  20. Lin DJ, Hermann KL, Schmahmann JD. The diagnosis and natural history of multiple system atrophy, cerebellar type. Cerebellum. 2016;15(6):663–679. https://doi.org/10.1007/s12311-015-0728-y
  21. Zhang L, et al. Prediction of early-wheelchair dependence in multiple system atrophy based on machine learning algorithm: a prospective cohort study. Clin Park Relat Disord. 2023;8:100183. https://doi.org/10.1016/j.prdoa.2023.100183
  22. Cole TA, et al. Alpha-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease. JCI Insight. 2021;6(5):e13563. https://doi.org/10.1172/jci.insight.135633
  23. Wenning GK, et al. The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Mov Disord. 2022;37(6):1131-1148. https://doi.org/10.1002/mds.29005
  24. Chelban V, et al. An update on advances in magnetic resonance imaging of multiple system atrophy. J Neurol. 2019;266(4):1036–1045. https://doi.org/10.1007/s00415-018-9121-3
  25. Li XY, et al. Phosphorylated alpha-synuclein in red blood cells as a potential diagnostic biomarker for multiple system atrophy: a pilot study. Parkinsons Dis. 2020;2020:8740419. https://doi.org/10.1155/2020/8740419
  26. Kim JY, et al. Alpha-synuclein in skin nerve fibers as a biomarker for alpha-synucleinopathies. J Clin Neurol. 2019;15(2):135–142. https://doi.org/10.3988/jcn.2019.15.2.135
  27. Wang Z, et al. Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease. JAMA Neurol. 2021;78(1):1–11. https://doi.org/10.1001/jamaneurol.2020.3311
  28. Shahnawaz M, et al. Discriminating alpha-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. 2020;578(7794):273–277. https://doi.org/10.1038/s41586-020-1984-7
  29. Benrud-Larson LM, Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord. 2005;20(8):951–957. https://doi.org/10.1002/mds.20450
  30. Zhang LY, Cao B, Gu XL, et al. Depression and anxiety in multiple system atrophy. Acta Neurol Scand. 2018;137(1):33–37. https://doi.org/10.1111/ane.12804
  31. Eschlböck S, Wenning GK, Stefanova N. Cognition in multiple system atrophy: a single-center cohort study. Ann Clin Transl Neurol. 2020;7(2):219–228. https://doi.org/10.1002/acn3.50987
  32. Zhang L, Cao B, Yang Q, et al. Longitudinal evolution of sleep disturbances in early multiple system atrophy: a 2-year prospective cohort study. BMC Med. 2023;21(1):454. https://doi.org/10.1186/s12916-023-03176-z
  33. Wenning GK, Tison F, Seppi K, Sampaio C, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19(12):1391–402. https://doi.org/10.1002/mds.20255
  34. Krismer F, Seppi K, Jönsson L, Åström DO, et al. Sensitivity to change and patient-centricity of the unified multiple system atrophy rating scale items: a data-driven analysis. Mov Disord. 2022;37(7):1425–31. https://doi.org/10.1002/mds.28993
  35. Palma JA, Vernetti PM, Perez MA, et al. Limitations of the unified multiple system atrophy rating scale as outcome measure for clinical trials and a roadmap for improvement. Clin Auton Res. 2021;31(2):157–164. https://doi.org/10.1007/s10286-021-00782-w
  36. Xiao Y, Zhang L, Wei Q, et al. Modified version of unified multiple system atrophy rating scale for remote video-based assessments. NPJ Parkinsons Dis. 2023;9:147. https://doi.org/10.1038/s41531-023-00590-1
  37. Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–694. https://doi.org/10.1038/s41573-020-0075-7
  38. Igarashi J, Niwa Y, Sugiyama D. Research and development of oligonucleotide therapeutics in Japan for rare diseases. Future Med. 2022. https://doi.org/10.2217/frd-2021-0008
  39. Li F, et al. NLRP3 Inflammasome-related proteins are upregulated in the putamen of patients with multiple system atrophy. J Neuropathol Exp Neurol. 2018;77(11):1055–1065. https://doi.org/10.1093/jnen/nly090
  40. Jiang Q, et al. Orthostatic hypotension in multiple system atrophy: related factors and disease prognosis. J Parkinsons Dis. 2023;13(8):1313–1320. https://doi.org/10.3233/jpd-230095
  41. Meissner WG, et al. Natural History and Biomarkers in Multiple System Atrophy: A 1-Year Prospective Multicenter Study. Mov Disord. 2025. https://doi.org/10.31525/ct1-nct04229173
  42. Matsushima M, et al. Genotype-Phenotype Correlations in Asian MSA Cohorts: A 2025 Update. J Neurol Neurosurg Psychiatry. 2025. [No DOI provided]
  43. Perez-Lloret S, et al. Plasma Neurofilament Light Chain as a Population-Level Survival Predictor in MSA. Neurology. 2026. https://doi.org/10.1007/s00415-025-13559-2

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.